The UK and US have hammered out a landmark trade agreement that will keep zero import taxes on British medicine shipments entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to boost expenditure on drugs through the NHS. This move guarantees that import taxes on these key goods will remain at nothing for a duration of three years.
This deal comes after recent statements to hike import taxes on patented pharmaceutical imports, with figures discussed up to one hundred percent.
"This agreement with the Britain bolsters the global environment for new treatments and brings long-overdue balance to U.S.–U.K. medicine commerce," a statement said.
Economic Significance
Medicines represent one of the the United Kingdom's most significant exports to the United States, which is by far the biggest market for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period leading up to September, the UK shipped drugs valued at billions to the US. This figure accounted for nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards jobs, increases funding and sets the stage for the UK to emerge as a global hub for life sciences," a government official remarked.
Key UK Commitments
The agreement involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to increase overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, repayments were more than twenty percent.
Broader Context
The pact follows a protracted dispute between the sector and the ministers over medicine costs and regulatory access.
This friction were exacerbated by claims that US consumers were charged several times more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been directed toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its spending on drugs had decreased as a percentage of its overall budget over the last ten years.
